Mode of action of the mitochondrial clinical-stage drug candidate KH176: two birds, one stone
Khondrion presents Phase II KHENERGY trial data supporting Phase III development of KH176 in mitochondrial disease
Results of Phase 2 clinical trial with KH176 in adult mitochondrial disease patients will be presented at Dutch Life Sciences conference
New Patents granted for Khondrion’s mitochondrial disease lead compound KH176
Khondrion announces completion of patient recruitment and first-in-patient dosing in its KHENERGY study, a phase 2 clinical trial with KH176 in MELAS/MIDD and mixed mitochondrial syndromes
The KHENERGYC study: European Union EFRO grant to boost the development of Khondrion’s KH176 for children with mitochondrial disease
Khondrion initiates the KHENERGY study, a phase 2 clinical trial of KH176 in MELAS/MIDD and mixed mitochondrial syndromes
New EU research project REMIX joins forces between universities’ research facilities and Khondrion
Khondrion reports successful outcome of KH176 Phase 1 Clinical trials
New EU research project SysMedPD joins forces between universities’ research facilities and Khondrion
Interview: Jan Smeitink, CEO of Khondrion, provides an overview of the latest developments regarding the company’s lead compound.
Khondrion receives Orphan Drug Designation from the European Commission for treatment of MELAS syndrome
Khondrion welcomes Hans Schikan to Advisory board
Khondrion Announces Start of Phase 1 Clinical Trial for Mitochondrial Disease
Khondrion appoints Edwin Spaans as Chief Medical Officer
Khondrion has received an Orphan Drug Designation from the FDA of its frontrunner compound KH176, in the treatment of inherited mitochondrial respiratory chain diseases
Khondrion will present its mitochondrial drug development strategy at the conference Innovation for Health in Amsterdam, The Netherlands on February 5th 2015.
Khondrion will present its mitochondrial drug development strategy at the AussieMit conference in Perth, Australia on December 1-3rd 2014.
Khondrion has received an Orphan Drug Designation from the European Commission of its frontrunner compound KH176, in the treatment of Leigh syndrome (EU/3/14/1336)
Khondrion will give a lecture on Mitochondrial Medicine at the Paediatric Neurology Association of Hong Kong Annual Scientific Meeting held on November 28th 2014.
Jan Smeitink, Khondrion's CEO and Professor of Mitochondrial Medicine at the Radboud University and its Medical Centre has been award a membership of the Academia Europaea.
Khondrion is one of the nominees for the 2013 Mercator Award
Kick-off meeting European MEET project in which Khondrion collaborates with 8 world-leading basic science and clinical centres of excellence to mobilise the critical mass of expertise
Article describing Khondrion's activities (in Dutch) in C2W
Khondrion supports the Mitochondrial Disease, translating biology into new treatments MRC conference in Cambridge, UK
Khondrion sponsor of the Euromit 2014 meeting in Tampere Finland
Interview by Prof. Jan Smeitink about the importance the Dutch PreSeed Grant Award had on the development of Khondrion
Jos Lamers, Khondrion's Corporate Advisory Board Members Chairman, has been appointed as CEO of Unilabs. For more info see www.unilabs.com
Prof. Jan Smeitink presented June 27 Khondrion's mitochondrial drug development strategy at the Gordon Conference on Bioenergetics, Andover, New Hampshire